Mild chronic small vessel disease, or cerebral small vessel disease (CSVD), is an umbrella term for a range of conditions ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Groundbreaking research unveils potential link between cytomegalovirus and Alzheimer's disease, offering new hope for ...

The Phase Ia trial is designed to assess the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

A new study has identified polyphosphate as a likely "mystery density" within fibrils associated with Alzheimer's and other ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc.

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc.